Celsius Therapeutics Appoints Tariq Kassum, M.D., as Chief Executive Officer

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for patients with autoimmune diseases and cancer, today announced the appointment of Tariq Kassum, M.D., as president and chief executive officer. Dr. Kassum brings nearly 20 years of experience in the biopharmaceutical industry to Celsius. He succeeds interim CEO Alexis Borisy, who will remain chairman of the companys board of directors.

Since its launch just over a year ago, Celsius has been making tremendous progress, and we are very excited to welcome Tariq as CEO to lead the company through its next phase of development, said Alexis Borisy, chairman of Celsius. Tariq brings a highly diverse skill set incorporating corporate development, strategy and business leadership. His extensive experience in multiple settings in the biotechnology industry will be instrumental in helping guide the company going forward.

Dr. Kassum joins the company from Obsidian Therapeutics, where he was a co-founder and served as chief operating officer and head of corporate development. During this time, Dr. Kassum helped build Obsidian into a leading platform technology company and played a central role in the companys strategic partnership with Celgene. Prior to Obsidian, Dr. Kassum spent seven years with Millennium Pharmaceuticals and Takeda, most recently as vice president, business development and strategy for Takeda Oncology, responsible for transactions, collaborations, alliance management and strategic planning. He also led Takedas global corporate development efforts, where he managed multiple acquisitions and divestitures. Prior to Takeda, Dr. Kassum was an analyst covering healthcare equities for institutional investment firms, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds. He began his career as an investment banker with CIBC World Markets serving clients in the biotechnology and specialty pharmaceuticals industries. He holds an M.D. from University of Toronto and an A.B. from Cornell University.

Celsius has integrated a unique combination of technologies, including single-cell genomics, machine learning, deep biology and drug discovery, all in the service of patients with serious conditions including autoimmune diseases and cancer, said Dr. Kassum. I am thrilled to be joining the company at this stage as we establish the power of this multifaceted approach to drive a portfolio of transformative therapies for patients.

About Celsius Therapeutics

Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer. Celsius was launched in 2018, is backed by Third Rock Ventures and GV (formerly Google Ventures), and is based in Cambridge, Mass. For more information, please visit www.celsiustx.com.

Katie Engleman
1AB
[email protected]